{
  "pmcid": "12505526",
  "sha256": "5c486ebbab6e9fd6eeefd581a3457e5229d7c4017e3e285fdee21850dbfa3e54",
  "timestamp_utc": "2025-11-09T22:30:55.911989+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.04053900234349,
    "reading_ease": 21.390048543689346,
    "word_count": 206
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Neuromuscular Blockade Antagonists in Surgical Patients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "35 randomised controlled trials (RCTs) involving 4275 patients"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were surgical patients requiring neuromuscular blockade reversal."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention was sugammadex, compared to neostigmine."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the impact of neuromuscular blockade antagonists on postoperative complications and recovery quality."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was time to Train-of-Four ratio (TOFR) ≥ 0.9, measured postoperatively."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Randomisation and allocation concealment methods were not specified."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding details were not provided."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "35 randomised controlled trials (RCTs) involving 4275 patients"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Sugammadex facilitated faster RNB reversal than neostigmine, with a quicker TOFR ≥ 0.9 (standardized mean difference [SMD] −3.45; 95% confidence interval [CI], −4.42 to −2.48)"
      },
      "Harms": {
        "score": 0,
        "evidence": "Adverse events were not detailed."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: PROSPERO CRD42024561006."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}